PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF ARQ 087, A NOVEL PAN-FGFR INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING INTRAHEPATIC CHOLAN-GIOCARCINOMA.

被引：0
|
作者：
Savage, R. [1 ]
Trinh, M. [2 ]
Dupuis, M. [2 ]
Marier, J. F. [2 ]
Schwartz, B. [1 ]
机构：
[1] ArQule, Burlington, MA USA
[2] Certara Strateg Consulting, Montreal, PQ, Canada
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / S1期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-091
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [1] A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
    Papadopoulos, K. P.
    El-Rayes, B. F.
    Tolcher, A. W.
    Patnaik, A.
    Rasco, D. W.
    Harvey, R. D.
    LoRusso, P. M.
    Sachdev, J. C.
    Abbadessa, G.
    Savage, R. E.
    Hall, T.
    Schwartz, B.
    Wang, Y.
    Kazakin, J.
    Shaib, W. L.
    BRITISH JOURNAL OF CANCER, 2017, 117 (11) : 1592 - 1599
  • [2] A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
    K P Papadopoulos
    B F El-Rayes
    A W Tolcher
    A Patnaik
    D W Rasco
    R D Harvey
    P M LoRusso
    J C Sachdev
    G Abbadessa
    R E Savage
    T Hall
    B Schwartz
    Y Wang
    J Kazakin
    W L Shaib
    British Journal of Cancer, 2017, 117 : 1592 - 1599
  • [3] A phase 1, dose-escalation, first-in-human study of ARQ 087, an oral pan-FGFR inhibitor, in adult subjects with advanced solid tumors
    Papadopoulos, K.
    Tolcher, A.
    Kittaneh, M.
    Patniak, A.
    Rasco, D.
    Chambers, G.
    Newth, G.
    Savage, R.
    Hall, T.
    Schwartz, B.
    Kazakin, J.
    LoRusso, P.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 125 - 125
  • [4] ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA)
    Mazzaferro, V.
    Shaib, W.
    Rimassa, L.
    Harris, W.
    Personeni, N.
    El-Rayes, B.
    Tolcher, A.
    Hall, T.
    Wang, Y.
    Schwartz, B.
    Kazakin, J.
    Busset, M. Droz Dit
    Cotsoglou, C.
    Papadopoulos, K.
    ANNALS OF ONCOLOGY, 2016, 27 : 109 - 109
  • [5] ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations.
    Mazzaferro, Vincenzo
    El-Rayes, Bassel F.
    Cotsoglou, Christian
    Harris, William Proctor
    Damjanov, Nevena
    Masi, Gianluca
    Rimassa, Lorenza
    Personeni, Nicola
    Braiteh, Fadi S.
    Zagonel, Vittorina
    Papadopoulos, Kyriakos P.
    Hall, Terence
    Wang, Yunxia
    Abbadessa, Giovanni
    Schwartz, Brian E.
    Kazakin, Julia
    Busset, Michele Droz Dit
    Shaib, Walid La Bib
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.
    Papadopoulos, Kyriakos P.
    Tolcher, Anthony W.
    Patnaik, Amita
    Rasco, Drew Warren
    Chambers, Glenda
    Beeram, Murali
    Savage, Ronald
    Hall, Terence
    Schwartz, Brian E.
    Kazakin, Julia
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors
    Sequist, Lecia V.
    Cassier, Phillippe
    Varga, Andrea
    Tabernero, Josep
    Schellens, Jan H.
    Delord, Jean-Pierre
    LoRusso, Patricia
    Camidge, D. Ross
    Hidalgo Medina, Manuel
    Schuler, Martin
    Campone, Mario
    Tian, G. Gary
    Wong, Steven
    Corral, Jesus
    Isaacs, Randi
    Sen, Suman K.
    Porta, Diana Graus
    Kulkarni, Swarupa G.
    Lefebvre, Caroline
    Wolf, Juergen
    CANCER RESEARCH, 2014, 74 (19)
  • [8] Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis
    Zheng, Xinyi
    Wang, Hang
    Deng, Junyue
    Yao, Minghe
    Zou, Xiuhe
    Zhang, Fan
    Ma, Xuelei
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [9] A phase I pharmacodynamic and pharmacokinetic study of a Ras inhibitor, PRLX 93936, in patients with advanced solid tumors
    Ramanathan, R. K.
    Rosen, P. J.
    Wagner, A. J.
    Sahasrabudhe, S.
    Weiss, G. J.
    Lee, P.
    Fuerst, M.
    Robbins, P.
    Litka, P.
    Von Hoff, D. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors
    Steele, Nicola L.
    Plumb, Jane A.
    Vidal, Laura
    Tjornelund, Jette
    Knoblauch, Poul
    Rasmussen, Annie
    Ooi, Chean Eng
    Buhl-Jensen, Peter
    Brown, Robert
    Evans, T. R. Jeffry
    DeBono, Johann S.
    CLINICAL CANCER RESEARCH, 2008, 14 (03) : 804 - 810
12345